L.J. Altfest & Co’s Sarepta Therapeutics SRPT Stock Holding History

L.J. Altfest & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,351	Closed	-$286K	–	359
2024 Q4	$286K	Buy	+2,351	New	+$288K	0.04%	275
2024 Q3	–	Sell	-1,931	Closed	-$305K	–	367
2024 Q2	$305K	Sell	1,931 -760	-28%	-$97.6K	0.04%	254
2024 Q1	$348K	Buy	+2,691	New	+$330K	0.05%	237
2021 Q4	–	Sell	-3,760	Closed	-$348K	–	269
2021 Q3	$348K	Buy	3,760 +29	+0.8%	+$2.23K	0.07%	183
2021 Q2	$290K	Buy	3,731 +22	+0.6%	+$1.67K	0.06%	212
2021 Q1	$276K	Buy	3,709 +926	+33%	+$85.4K	0.07%	215
2020 Q4	$474K	Buy	2,783 +815	+41%	+$121K	0.12%	133
2020 Q3	$276K	Buy	+1,968	New	+$299K	0.07%	180
2020 Q1	–	Sell	-1,629	Closed	-$210K	–	226
2019 Q4	$210K	Buy	+1,629	New	+$164K	0.05%	186

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

L.J. Altfest & Co's SRPT Position: Q1 2025 in Review

L.J. Altfest & Co sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,351 shares — an estimated $286K sold.

L.J. Altfest & Co first reported a position in SRPT in Q4 2019 and held it in 9 quarters. The position peaked at $474K in Q4 2020. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

L.J. Altfest & Co reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
L.J. Altfest & Co sold 2,351 Sarepta Therapeutics shares in Q1 2025, an estimated $286K.
L.J. Altfest & Co first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 9 quarters.
L.J. Altfest & Co's Sarepta Therapeutics position peaked at $474K in Q4 2020.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on L.J. Altfest & Co's 13F filing for Q1 2025, filed 9 May 2025.